NICE Gives OK for Merck’s Keytruda for Melanoma

NICE has recommended NHS coverage for Merck’s Keytruda (pembrolizumab) for the treatment of certain melanoma patients.

The institute’s recommendation is for adults who have melanoma that has progressed to the lymph nodes. The recommendation applies to patients that have already undergone surgery to remove their melanoma.

The drug will become available through the NHS after it receives a marketing authorization, anticipated in early December.